Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 14/20 | 0.66 |
| ▸ | PIM1 | P11309 | 5/20 | 0.56 |
| ▸ | PIM3 | Q86V86 | 5/20 | 0.56 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11886271 | 0.91 | CHEK1 (0.67) | CHEK1PIM1PIM3PIM2 | |
| SCHEMBL11886272 | 0.88 | CHEK1 (0.58) | CHEK1PIM1PIM3PIM2PRKCA | |
| SCHEMBL14217915 | 0.86 | CHEK1 (0.59) | CHEK1PIM1PIM3PIM2PRKCA | |
| SCHEMBL11886308 | 0.83 | CHEK1 (0.58) | CHEK1PIM1PIM3PIM2PRKCA | |
| SCHEMBL14207423 | 0.83 | PIM1 (0.56) | CHEK1PIM1PIM3PIM2PRKCA | |
| SCHEMBL11886244 | 0.83 | CHEK1 (0.58) | CHEK1PIM1PIM3PIM2PRKCA | |
| SCHEMBL11886268 | 0.82 | CHEK1 (0.57) | CHEK1PIM1PIM3PIM2PRKCA | |
| SCHEMBL11886265 | 0.81 | CHEK1 (0.56) | CHEK1PIM1PIM3 | |
| SCHEMBL11886255 | 0.81 | CHEK1 (0.54) | CHEK1PIM1PIM3PIM2PRKCA | |
| SCHEMBL11886256 | 0.81 | CHEK1 (0.55) | CHEK1PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078002-B1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8227605-B2 | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | SCHERING CORPORATION (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227605-B2 | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | SCHERING CORPORATION (US) | 2012-07-24 | — | — | US | disclosed |
| US-20100055090-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-03-04 | — | — | US | disclosed |
| US-20100055090-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-03-04 | — | — | US | disclosed |
| WO-2008054701-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055090-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MAPK15, CDK15, MAP3K15 | CHEK1 395/4885PIM1 1445/4885PIM3 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.